Gut microbiota is associated with response to 131I therapy in patients with papillary thyroid carcinoma

• DOI: 10.1007/s00259-022-06072-5
• Publication Date: 2022-12-13T09:03:05Z
• Authors: Lei Zheng; Linjing Zhang; Li Tang; Dingde Huang; Deng Pan; Wei Guo; Song He; Yong Huang; Yu Chen; Xu Xiao; Bo Tang; Jing Chen
• Keywords: Radioiodine therapy; Hormone Therapy

Radioactive iodine (131I) therapy is a conventional post-surgery treatment widely used for papillary thyroid carcinoma (PTC). Since 131I orally administered, we hypothesize that it may affect gut microbiome. This study aims to investigate alterations of intestinal microbiome caused by in PTC patients and explore its association with response therapy.Fecal samples 60 pre- post-131I were collected characterize the therapy-induced microbiota using 16S rRNA gene sequencing. According inclusion criteria, sequence data 40 out patients, divided into excellent (ER) group non-excellent (NER) group, recruited possible connection between therapy. Multivariate binary logistic regression was employed construct predictive model therapy.Microbial richness, diversity, composition tremendously altered A significant decline Firmicutes Bacteroides (F/B) ratio observed also led changes microbiome-related metabolic pathways. Discrepancies β diversity found ER NER groups both Furthermore, p value 0.003 an overall percentage correct 80.0% established, three variables including lymph node metastasis, relative abundance g_Bifidobacterium g_Dorea. Among them, g_Dorea identified be independent predictor (p = 0.04).For first time, present demonstrates microbial dysbiosis reveals previously undefined role as ablation response. G_Dorea potential targets clinical intervention improve post-operative patients.ChiCTR2100048000. Registered 28 June 2021.